Navigation Links
United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
Date:10/11/2011

on or qualification under the securities laws of any state.  [uthr-g]

Forward-looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, (i) the Company's intention to offer its notes, subject to market and other conditions; (ii) the Company's expectations regarding granting the initial purchaser an over-allotment option, (iii) the Company's intention to enter into a convertible note hedge transaction and a warrant transaction and the intention of the counterparty to such transactions and/or its affiliates, to enter into various derivative transactions; (iv) the Company's intention to use the net proceeds of the offering, together with cash on hand, to enter into an accelerated share repurchase transaction and (v) the Company's expectations regarding the effect on the price of its common stock from the transactions.  These forward-looking statements are subject to certain risks and uncertainties, such as those described in the Company's periodic and other reports filed with the Securities and Exchange Commission, which could cause actual results to differ materially from anticipated results.  Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in the Company's periodic reports and documents filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  The Company claims the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.  The information in this press release is provided as of its date, and the Company assumes no obligation to update or revise t
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
2. Full-day "United Nations" Online Investor Conference: October 6th at RetailInvestorConferences.com
3. United Therapeutics Corporation Reports Second Quarter 2011 Financial Results
4. FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States
5. Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
6. United Therapeutics Corporation To Announce Second Quarter 2011 Financial Results Before Market Open on Thursday, July 28, 2011
7. United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial
8. United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results
9. United Therapeutics Corporation to Announce Fourth Quarter and Annual 2010 Financial Results Before Market Open on Tuesday, February 15, 2011
10. United Therapeutics Corporation Reports Third Quarter 2010 Financial Results
11. United Therapeutics Corporation to Announce Third Quarter 2010 Financial Results Before Market Open on Thursday, October 28, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the device," Nobel laureate Herbert Kroemer famously observed, ... at the junctures where layers of different materials ... interfaces between layers of metal oxides are becoming ... as spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing ...
(Date:1/15/2014)... 2014 Cynvenio, a cancer diagnostics company ... genomic analysis of tumor cells in the bloodstream, today ... cancer decision support application powered by CollabRx, Inc. ... genomic test, Therapy Finder will provide breast cancer patients ...
(Date:1/15/2014)... January 15, 2014 More than 5 ... about 1 in 3 seniors will die with Alzheimer’s ... These jaw-dropping figures have shocked many Americans into looking ... help prevent these tragic age-related cognitive disorders. Jonathan Weisman, ...
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
Breaking Biology Technology:A deeper look at interfaces 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... Licensing Opportunities , , ... KANSAS CITY, Mo. , May 17 ... Inc., today announced that it is continuing its strategic international expansion ... group of leading research hospitals and institutes based in Toronto, ...
... , May 17 /PRNewswire-FirstCall/ - Aeterna Zentaris ... drug development company specialized in oncology and endocrinology, today ... orphan medicinal product designation from the Committee for Orphan ... its compound AEZS-108 for the treatment of ovarian cancer. ...
... China, May 17 /PRNewswire-Asia-FirstCall/ -- Biostar,Pharmaceuticals, Inc. (Nasdaq: ... of a leading over-the-counter Hepatitis B medicine, Xin,Aoxing Oleanolic Acid ... financial results of the first quarter ended March,31, 2010 ... increased 66.0% to $12.4 million, -- Q1 ...
Cached Biology Technology:The iBridge Network Adds Toronto's University Health Network as First Canadian Partner 2The iBridge Network Adds Toronto's University Health Network as First Canadian Partner 3Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency 2Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency 3Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 2Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 3Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 4Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 5Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 6Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 7Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 8Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 9Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 10Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 11Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 12Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 13
(Date:4/22/2014)... of Montana,s Wildlife Biology Program, co-wrote a research paper published ... of Sciences on how streamwater chemistry varies across a ... Lowe and co-authors from ... the Cary Institute of Ecosystem Studies, the University of Connecticut ... water samples collected every 10 meters along 32 tributaries of ...
(Date:4/22/2014)... HOUSTON (April 22, 2014) Biotechnology scientists must ... for new patent and licensing guidelines, according to a ... Policy. , Published in the current issue of the ... on the June 2013 U.S. Supreme Court ruling in ... Genetics that naturally occurring genes are unpatentable. The court ...
(Date:4/22/2014)... nanotechnology expert will present a poster titled ... 7th International Nanotoxicology Congress to be held ... Monita Sharma will outline a strategy consistent with the ... " Toxicity Testing in the 21st Century: A Vision ... methods involving human cells and cell lines for mechanistic ...
Breaking Biology News(10 mins):New research focuses on streamwater chemistry, landscape variation 2New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3
... adults with the blood cancer mixed-lineage leukemia (MLL) typically have ... birthdays. Although there are varying causes of MLL, most cases ... and the AF4 genes. When the ... cancer-causing oncogene is created. Although researchers have known that the ...
... engineering holds great promise for the treatment of conditions ... injuries. However, bone and cartilage currently produced in ... the body so they,re not clinically viable. Dr. ... of Medicine & Dentistry at The University of Western ...
... 2008 -- A rat thought extinct for 11 million years ... new species discovered in the Greater Mekong Region of Southeast ... launched by World Wildlife Fund (WWF). First ... discovered or newly identified by science between 1997 and 2007 ...
Cached Biology News:Tracking the molecular pathway to mixed-lineage leukemia 2Building better bones and tissue in the lab 2Over 1,000 species discovered in the Greater Mekong in past decade 2
... a user-friendly statistical software package for scientists ... statistical analysis without being a statistical expert.Just ... and research and SigmaStat suggests the appropriate ... tests underlying assumptions and suggests another test ...
... Novexin offers bespoke, cost-effective solutions for complex protein ... extensive expertise and experience to help you develop a ... , , ... , transfer all methodology ...
... is a chemiluminescent signal enhancing reagent ... boost the signal obtained with all ... ChemiLucent™ Plus is derived from a ... complex- or chemiluminescent substrate enhancers, ChemiLucent™ ...
... GeneSpring Workgroup solution is a highly ... mining expression data in a workgroup ... deployed in over 40 leading pharmaceutical, ... worldwide. GeneSpring Workgroup streamlines genomics research ...
Biology Products: